Drug Trial Radar · NCT07830433
Evaluation of the Efficacy of Zuberitamab Injection in Patients With Primary Membranous Nephropathy
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Dec 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- BioRay Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, open-label, cyclosporine-controlled, multicenter Phase III study. It aims to evaluate the efficacy, safety, pharmacokinetics and immunogenicity of zuberitamab versus cyclosporine in patients with primary membranous nephropathy, and provide evidence to support the expansion of zuberitamab's indication for primary membranous nephropathy. Approximately 150 study participants are expected to be enrolled in this trial and randomized in a 1:1 ratio to the HS006 1000 mg group (treatment group) and the cyclosporine group (control group), with 75 participants in each arm.
Conditions
- Primary Membranous Nephropathy
Interventions
Zuberitamab 1000mgDrug
administered at week0, week2, week24, week26 and week52
CyclosporineDrug
Initial dose of 3.5 mg/kg/d, oral administration, divided into two doses, taken 12 hours apart (Q12h)
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of participants who achieved Complete Response (CR) at week 104Time frame: Week 104
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhongshan Hospital Fudan University
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.